5,6-Methylenedioxy-2-aminoindane (commonly known as MDAI) is an entactogen substance of the aminoindane chemical class that produces entactogenic effects when administered.Notably, this compound primarily produces the non-stimulating effects of prototypical entactogens like MDMA such as sedation, muscle relaxation, and tactile enhancement.
5,6-methylenedioxy-2-aminoindane, was developed in the 1990s by a team led by David E. Nichols at Purdue University.
It acts as a putatively non-neurotoxic and highly selective serotonin releasing agent (SSRA) with neglible effects on dopamine and norepinephrine.
This reportedly limits its potential at producing overtly invigorating, prosocial or euphoric effects.
5,6-methylenedioxy-2-aminoindane,has been marketed alongside research chemical entactogens like 5-MAPB, 5-APB, and 6-APB as a legal, grey-market alternative to MDMA.
Very little data exists about the pharmacological properties,
metabolism, and toxicity of 5,6-methylenedioxy-2-aminoindane,, and it has a limited history of human use.
It is highly advised to use harm reduction practices if using this substance.